Wire · opportunities
BioNTech says lung cancer drug candidate prolonged lives in trial
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 14 September 2026 · Fusion42 review
BioNTech's drug candidate gotistobart showed a clinically meaningful overall survival benefit in late-stage trials for squamous non-small cell lung cancer patients who progressed despite prior immunotherapy and chemotherapy, nearly doubling survival compared to standard chemotherapy.
This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it.
◆ ◆ The Wire takeaway
You now have a proven candidate that extends survival in a tough lung cancer segment, making this a launching point for clinical and commercial moves. Competitors and collaborators will quickly reassess their portfolios and partnerships around this drug.
◆ Coverage
2 sources · 14 Sep 2026
◆ Related on Wire
◆ Topics